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Edited by Vladimir SkulachevAbstract Senescence marker protein-30 (SMP30) was origi-
nally identiﬁed as a novel protein in the rat liver, the expression
of which decreases androgen-independently with aging. We have
now characterized a unique property of SMP30, the hydrolysis
of diisopropyl phosphoroﬂuoridate (DFP), which is similar to the
chemical warfare nerve agents sarine, soman and tabun. Hydro-
lysis of DFP was stimulated equally well by 1 mM MgCl2,
MnCl2 or CoCl2, to a lesser extent by 1 mM CdCl2 but not at all
by 1 mM CaCl2. No
45Ca2þ-binding activity was detected for
puriﬁed SMP30, suggesting that SMP30 is not a calcium-
binding protein, as others previously stated. Despite the sequence
similarity between SMP30 and a serum paraoxonase (PON), the
inability of SMP30 to hydrolyze PON-speciﬁc substrates such
as paraoxon, dihydrocoumarin, c-nonalactone, and d-dodecan-
olactone indicate that SMP30 is distinct from the PON family.
We previously established SMP30 knockout mice and have now
tested DFPase activity in their livers. The livers from wild-type
mice contained readily detectable DFPase activity, whereas no
such enzyme activity was found in livers from SMP30 knockout
mice. Moreover, the hepatocytes of SMP30 knockout mice were
far more susceptible to DFP-induced cytotoxicity than those
from the wild-type. These results indicate that SMP30 is a
unique DFP hydrolyzing enzyme in the liver and has an
important detoxiﬁcation eﬀect on DFP. Consequently, a reduc-
tion of SMP30 expression might account for the age-associated
deterioration of cellular functions and enhanced susceptibility to
harmful stimuli in aged tissue.
 2004 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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[1]. Amounts of SMP30 signiﬁcantly decrease with aging in an
androgen-independent manner [1–3], and the amino acid se-
quences of this 34-kDa protein are highly conserved among
vertebrates [2,4,5]. Recently, several SMP30 homologues were
also discovered in non-vertebrates such as Drosophila [6,7],
Sarcophaga [7] and ﬁreﬂies [8]. By RT-PCR analysis, SMP30
transcripts have been detected in multiple tissues including the
liver, kidney, lung, testes and cerebrum [9]. The human SMP30
gene is located in the p11.3–q11.2 segment of the X chromo-
some [4]. SMP30 regulates Ca2þ kinetics involved in the
plasma membrane Ca2þ-pumping activity of HepG2 and LLC-
PK1 cells showing that SMP30 could rescue cells from an
apoptotic death induced by a high intracellular Ca2þ level
([Ca2þ]i) [10,11]. According to a database search, SMP30 has a
domain similar to that of bacterial and yeast RNA polymerase
[12]. In cultured hepatocytes, SMP30 is distributed in both the
cytoplasm and nuclei [12]. Since SMP30 is present in the nu-
clei, this protein may regulate gene expression such as in
transcription.
To clarify the relationships between SMP30’s decrease
and age-associated organ disorders, we established SMP30
knockout mice [13]. Throughout our experiments in vitro
and in vivo, the livers of these knockout animals were far
more susceptible to TNF-a- and Fas-mediated apoptosis
than those from the wild-type. Interestingly, livers of
SMP30 heterozygous mice showed intermediate susceptibil-
ity to Fas-induced apoptosis. Thus, SMP30 acts to protect
cells from apoptosis. Moreover, histological and biochemical
analyses of livers from SMP30 knockout mice showed ab-
normal accumulations of neutral lipids and phospholipids
such as phosphatidylethanolamine, cardiolipin, phosphati-
dylcholine, phosphatidylserine and sphingomyelin [14]. This
abnormal lipid metabolism must increase the tissue’s sus-
ceptibility or resistance to apoptosis. Such changes of
SMP30 expression might, then, account for the deterioration
of cellular functions and susceptibility to harmful stimuli in
aged tissues.
In 1999, Billecke et al. [15] puriﬁed from mouse livers a novel
soluble enzyme capable of hydrolyzing diisopropyl phosp-
horoﬂuoridate (DFP) and similar to the nerve-paralyzing agents
isopropyl methylphosphonoﬂuoridate (sarine), ethyl-N-di-
methyl phosphoramidocyanidate (tabun) and pinacolyl meth-
ylphoshonoﬂuoridate (soman). Sequencing the partial peptideblished by Elsevier B.V. All rights reserved.
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identical amino acid sequence to that of mouse SMP30. How-
ever, the DFPase activity of the cell lysate expressing re-
combinant SMP30 was too low for deﬁnitive identiﬁcation.
In this study,we puriﬁed SMP30 from rat livers and conﬁrmed
its DFPase activity. Moreover, by using our previously estab-
lished SMP30knockoutmice,we clearly showed that SMP30 is a
unique enzyme that hydrolyzes DFP in the liver.2. Materials and methods
2.1. Materials and chemicals
Phenyl acetate, paraoxon, dihydrocoumarin, c-nonalactone and d-
dodecanolactone were purchased from Sigma–Aldrich (St. Louis, MO,
USA). DEAE-Sephacel, Phenyl Sepharose CL-4B and Sephacryl S-200
HR were purchased from Amersham Biosciences (Piscataway, NJ,
USA). DFP and other reagents were purchased from Wako Pure
Chemical (Osaka, Japan).
2.2. Animals
Male Wister rats, 3–9 months of age, were obtained from the
Animal Facility at Tokyo Metropolitan Institute of Gerontology.
SMP30 knockout mice were generated by gene targeting [13]. In this
study, we used male SMP30 knockout (SMP30Y/)) mice and male
wild-type (SMP30Y/+) mice at an age of 3 months. Heterozygous
male mice do not exist, because the SMP30 gene is located on the X
chromosome. Mice were maintained on 12 h light/dark cycles in a
controlled environment and fed ad libitum. The Animal Care and
Use Committee of Tokyo Metropolitan Institute of Gerontology
approved the protocol of animal experiments performed in the
present study.
2.3. Puriﬁcation of rat SMP30
All puriﬁcation procedures were carried out at 0–4 C unless
otherwise stated. Rat livers (20 g) were homogenized with 8 vol. of
ice-cold homogenization buﬀer (10 mM Tris–HCl, pH 8.0, 1 mM
MgCl2, 1 mM dithiothreitol, 1 mM phenyl-methanesulfonyl ﬂuoride),
in a Polytron homogenizer. The homogenate was centrifuged at
7000 g for 30 min. The supernatant was fractionated by ammonium
sulfate precipitation, and the fraction precipitated from 45% to 70%
saturation was suspended in buﬀer A (10 mM Tris–HCl, pH 8.0, 1
mM MgCl2), and thoroughly dialyzed against the same buﬀer. In-
soluble materials were removed by centrifugation at 10 000 g for 20
min, and the supernatant was applied to a DEAE-Sephacel column
(1.4 25 cm) pre-equilibrated with buﬀer A. Elution was performed
with a linear gradient of 0–0.35 M NaCl in 400 ml of buﬀer A. The
fractions containing SMP30 were determined by dot-blot analysis
using mouse anti-recombinant human SMP30 monoclonal antibody.
The SMP30 fractions were pooled and brought to 45% saturation in
ammonium sulfate, then dialyzed against the buﬀer A saturated with
45% ammonium sulfate. Insoluble materials were removed by cen-
trifugation and the supernatant was applied to a Phenyl Sepharose
CL-4B (1.0 13 cm) pre-equilibrated with buﬀer A saturated with
45% ammonium sulfate. Elution was performed with a linear gradi-
ent of 45 to 0% ammonium sulfate in 80 ml of buﬀer A. The SMP30
fractions were pooled and concentrated by ammonium sulfate pre-
cipitation. The concentrated solution was subjected to gel ﬁltration
on Sephacryl S-200 HR (1.0 47 cm) equilibrated with buﬀer A
containing 0.2 M NaCl. Each SMP30 fraction was stored at )70 C
until use.
2.4. Protein determination and SDS–polyacrylamide gel electrophoresis
The protein content of fractions from the column chromatographic
separations was monitored by measuring the absorbance at 280 nm.
The protein concentration in samples was determined by the BCA
protein assay (Pierce Biotechnology, Inc., Rockford, IL, USA) using
bovine serum albumin as a standard. SDS–PAGE was performed on
vertical slab gels (1 mm 9 cm) containing 14% (w/v) acrylamide and
0.25% (w/v) N,N0-methylenebisacrylamide, by the method of Laemmli
[16]. The proteins were visualized by Quick CBB (Wako Pure Chem-
ical, Osaka, Japan).2.5. DFPase activity
DFPase activity was measured as described by Billecke et al. [15].
Brieﬂy, the reaction cuvette contained 5.74 mMDFP in 2 mMHEPES,
pH 8.0, 1 mM MgCl2, 0.004% phenol red in a total volume of 1 ml.
Reactions were initiated by adding the enzyme and the acid production
rate was followed by monitoring increased absorbance at 422 nm at 25
C. A calibration curve was constructed using a range of HCl con-
centrations, and an equation relating slope (the change in optical
density per unit time) to acid production was derived: 1.900 106
(DOD/Dtime)/sample volume (ll)¼nmol/ml. The slope of the absor-
bance trace was determined over 5–10 min to measure the rate of acid
production. For determination of divalent cations’ requirement for
DFPase activity, 1 mMMgCl2, CaCl2, MnCl2, CoCl2 and CdCl2 were
used.
For determination of DFPase activity in the liver, livers were re-
moved from mice and homogenized with ice-cold homogenization
buﬀer (10 mM Tris–HCl, pH 8.0, and 1 mM phenyl-methanesulfonyl
ﬂuoride) for 30 s at high speed with a Polytron homogenizer. The
homogenate was centrifuged at 10 000 g for 10 min. The protein
concentration of crude extract was adjusted to 5 mg/ml. The reaction
was initiated by the addition of crude extract (0.2 mg) in the presence
of 1 mM MgCl2.
2.6. Arylesterase activity
Arylesterase activity was determined as described by Gan et al.
[17]. Brieﬂy, the cuvette contained 1 mM phenylacetate in 20 mM
Tris–HCl, pH 8.0, and 1 mM CaCl2 in a total volume of 1 ml. The
reaction was initiated by adding enzyme, and the increase in absor-
bance at 270 nm was recorded. The amount of phenol was calculated
from the molar diﬀerence extinction coeﬃcient, 1310 M1 cm1.
Blanks without enzyme were used to correct for spontaneous hy-
drolysis of phenylacetate. For determination of divalent cations’ re-
quirement for arylesterase activity, 1 mM CaCl2, MgCl2, MnCl2,
CoCl2 and CdCl2 were used.2.7. PON activity
Paraoxonase (PON) activity was measured with 1 mM paraoxon in a
total volume of 1 ml. Enzymatic activity was measured in 50 mM Tris–
HCl, pH 8.0. The reaction was initiated by the addition of enzyme, and
the increase in absorbance at 412 nm was recorded. The amount of p-
nitrophenol was calculated from the molar diﬀerence extinction coef-
ﬁcients 17 100 M1 cm1.
2.8. Other enzyme activities
Hydrolysis of dihydrocoumarin was monitored by the increase in
UV absorbance at 270 nm. In a typical experiment, a cuvette contained
1 mM substrate in 50 mM Tris–HCl, pH 8.0, in a total volume of 1 ml.
The molar diﬀerence extinction coeﬃcients used to calculate the rate of
hydrolysis were 1295 M1 cm1 [18].
Hydrolysis activities of c-nonalactone and d-dodecanolactone were
followed by a colorimetric assay with phenol red [18].
2.9. Isolation and culture of mouse hepatocytes
Mouse hepatocytes were isolated by the collagenase perfusion
method as described [19]. Brieﬂy, each liver was perfused in situ
through the vena cava with EGTA solution containing 0.5 mM
EGTA, 5 mM glucose, 136 mM NaCl, 5.3 mM KCl, 0.3 mM
Na2HPO4, 0.4 mM KH2PO4, and 10 mM HEPES, pH 7.2, at a rate of
15 ml/min. After that perfusion, the ﬁrst solution was replaced with a
solution containing 0.5 mg/ml collagenase, 0.05 mg/ml trypsin inhibi-
tor, 4.5 mM CaCl2, 136 mM NaCl2, 5.3 mM KCl, 0.3 mM NaH2PO4,
0.4 mM KH2PO4, and 10 mM HEPES, pH 7.4. After the second
perfusion, the livers were removed and ﬁltered through nylon mesh
(100 lm) and then washed three times with Hanks’ Balanced Salt
Solution and twice with Williams medium E to remove non-paren-
chymal cells. Final hepatocyte preparations were suspended at
1.25 105 cell/ml in Williams medium E containing 0.1 mg/ml apro-
tinin and 109 M dexamethasone supplemented with 5% fetal calf se-
rum and then placed into culture plates coated with rat type I collagen
(Sigma–Aldrich). Cells were cultured at 37 C under 5% CO2 in air for
3 h to allow attachment to the wells, then the medium was replaced
with serum-free Williams medium E containing 0.1 mg/ml aprotinin
and 109 M dexamethasone. Cell viability was determined by trypan
blue dye exclusion before plating.
Table 1
Summary of puriﬁcation and yields of SMP30 from the rat liver
Total protein (mg) Total DFPase activity (nmol/min) Speciﬁc activity (nmol/min/mg) Overall puriﬁcation (fold)
Soluble fraction 1830 55 900 31 1
DEAE-Sephacel 140 19 100 136 4
Phenyl Sepharose CL-4B 7.84 4100 523 17
Sephacryl S-200 HR 0.84 1270 1512 49
Wister rat livers (20 g) were used for preparing the liver soluble fraction. The puriﬁcation steps and DFPase activity measurement are described in
Section 2.
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Mouse hepatocytes were incubated with various concentrations of
DFP for 24 h at 37 C. Then, cell viability was determined by the
XTT assay using the Cell Proliferation Kit II (XTT) (Roche Diag-
nostics, Mannheim, Germany). Brieﬂy, the medium was replaced with
phenol red-free Williams medium E containing 0.1 mg/ml aprotinin,
109 M dexamethasone, and XTT solution (0.3 mg/ml). After incu-
bation for 4 h at 37 C, absorbance at 492 nm was measured with a
Multiscanner Autoreader (Emax, Molecular Devices, Sunnyvale,
CA, USA).0
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A3. Results
3.1. Puriﬁcation of rat SMP30
The puriﬁcation protocol and yield of SMP30 from rat livers
are summarized in Table 1. Electrophoretic proﬁles of each
fraction appear in Fig. 1. The purity of the SMP30 fraction
obtained by Sephacryl S-200 HR column chromatography was
demonstrated by the single band it yielded with an apparent
Mr of 34 000 estimated by SDS–PAGE.
3.2. DFPase activity of puriﬁed SMP30
Using the puriﬁed rat SMP30, we measured DFPase activity
under standard assay conditions in the presence of 1 mM
MgCl2. The results indicated that puriﬁed SMP30 hydrolyzed
DFP with speciﬁc activity of 998 nmol/min/mg of protein in a
dose-dependent manner between 0 and 40 lg of protein
(Fig. 2A). The time course of DFP hydrolysis during the ﬁrst
10 min was linear, i.e., no lag phase occurred (data not shown).
Without MgCl2 present, SMP30 did not produce DFPase ac-Fig. 1. SDS–PAGE proﬁle of protein samples from each puriﬁcation
step. Aliquots of material from each step of the puriﬁcation were
subjected to SDS–PAGE, and the gel was stained with Quick CBB.
Lane 1, liver soluble fraction (9 lg of protein); lane 2, DEAE-Sephacel
pool (6 lg of protein); lane 3, Phenyl Sepharose CL-4B pool (1 lg of
protein); lane 4, Sephacryl S-200 HR pool (0.8 lg of protein).tivity; however, at a concentration of 1 mM, Mg2þ eﬀectively
incited DFPase activity (Fig. 2B), and that amount was then
used in all subsequent experiments here.
Since the activity of SMP30 seemed to entail an absolute re-
quirement forMg2þ, other divalent cationswere also tested.At a0
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Fig. 2. DFPase activity of SMP30. (A) Dose-response curve of DFPase
activity stimulated by SMP30. Rat SMP30 was puriﬁed as described in
Section 2. DFPase activity was determined by using increasing doses of
SMP30 in the presence (closed circle) or absence (closed triangle) of
1mM MgCl2. (B) Eﬀect of Mg
2þ on the hydrolysis of DFP by SMP30.
DFPase activity was determined by applying several concentrations of
MgCl2 in the presence of SMP30 (40 lg of protein). Values are ex-
pressed as an average of DFPase activity S.E.M. of three indepen-
dent experiments.
Table 2
Eﬀect of divalent cations on DFPase activity
Divalent cation Activity (%)
MgCl2 100
MnCl2 100
CoCl2 102
CdCl2 38
CaCl2 0
DFPase activity was measured in the presence of each divalent cation
at a concentration of 1 mM. The enzyme activity was expressed as the
percentage of MgCl2 with a speciﬁc activity of 341 nmol/min/mg of
protein. The results represent the average of three independent ex-
periments.
Table 3
PON substrate speciﬁcity of SMP30
Substrate Speciﬁc activity
(nmol/min/mg of protein)
DFP 998 71
Phenyl acetate 527 15
Paraoxon NDa
Dihydrocoumarin NDa
c-Nonalactone NDa
d-Dodecanolactone NDa
Hydrolyzing activity in each substrate was measured as described in
Section 2. The results represent the average S.E.M. of three inde-
pendent experiments.
aND, no detectable enzyme activity.
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Fig. 4. DFP-induced cell death. SMP30Y/+ and SMP30Y/) hepato-
cytes were incubated for 24 h in medium containing 0.01 mM and 1
60 Y. Kondo et al. / FEBS Letters 570 (2004) 57–62ﬁnal concentration of 1 mM in the standard assay mixture,
Mg2þ, Mn2þ, and Co2þ ions were equally as active as Mg2þ in
stimulating SMP30 to hydrolyze DFP (100%); however, the
Cd2þ ion was considerably less eﬀective (38%) (Table 2). In the
presence of Ca2þ ion, no DFPase activity was observed.
3.3. Substrate speciﬁcity of SMP30
According to a NCBI Conserved Domain Search using
the GenBank protein database, the rat SMP30 domain (103
amino acids, residues 138–240) bears close sequence simi-
larity to that of rat serum PON1 (100 amino acids, residues
208–307). Mammalian PON has three distinct isozymes:
PON1, PON2 and PON3; and these hydrolyze toxic orga-
nophosphates, carbamates and aromatic esters [20]. The rat
SMP30 domain showed 65% similarity to the PON1 domain
(Fig. 3). To determine the speciﬁcity of SMP30 for PON
substrates, we tested such substrates as phenylacetate,
paraoxon, dihydrocoumarin, c-nonalactone, and d-dodecan-
olactone (Table 3). SMP30 successfully hydrolyzed phenyl-
acetate with a speciﬁc activity of 527 nmol/min/mg of
protein in the presence of 1 mM CdCl2, but failed to hy-
drolyze paraoxon, dihydrocoumarin, c-nonalactone or d-
dodecanolactone.mM DFP. Percent survival was calculated relative to treatment with
0.01 mM DFP in SMP30Y/+ hepatocytes by XTT assay. Values are
expressed as an average percentage of survivalS.E.M. of four inde-
pendent experiments.3.4. DFPase activity in livers from SMP30 knockout
(SMP30Y/)) mice
To ascertain the ability of SMP30 to hydrolyze DFP, we
compared DFPase activity in the livers from SMP30Y/+ and
SMP30Y/) mice. Livers from SMP30Y/+ mice had 32 5
nmol/min/mg protein (n ¼ 5) of DFPase activity, whereas liv-
ers from SMP30Y/) mice had no detectable DFPase activity.
Thus, SMP30 is a unique enzyme that, when present in the
liver, eﬀectively hydrolyzes its content of DFP.3.5. DFP-induced cytotoxicity toward hepatocytes of SMP30Y/)
mice
To investigate the detoxiﬁcation eﬀect of SMP30 on DFP-
induced lysis, hepatocytes from SMP30Y/+ and SMP30Y/)SMP30 138 FPDHSVKKYFDQVDISNGLDWSLDH
PON1 208 YSPDKVRVVADGFDFANGIGISLDG
SMP30 193 VYKMEKDEQIPDGMCID-VEGKLWV
PON1 258 PLKVLSFDTLVDNISVDPVTGDLWV
Fig. 3. Sequence similarities of the rat SMP30 domain (103 amino acids, resid
307). Identical residues are shown with black boxes, and similar residues a
domain. SMP30 : GenBank Accession No. CAA48786; PON1: GenBank Amice were treated with increasing concentrations of DFP. The
extent of cell death was determined by XTT assay (Fig. 4).
Exposure to 0.01 mM DFP had no eﬀect on SMP30Y/+ he-
patocytes (100% survival); however, signiﬁcantly fewer
SMP30Y/) hepatocytes remained viable (about 65% survival)
after this treatment. Moreover, exposure to a higher concen-
tration of DFP (1 mM) decreased the viability of hepatocytes
from both SMP30Y/+ and SMP30Y/) mice. These results
clearly showed that hepatocytes without SMP30 are far moreKIFYYIDSLSYTVDAFDYDLPTGQISNRRT
KYVYIAELLAHKIHV--YE---KHANWTLT
ACY-NGGRVIRLDPETGKRLQTVKL  240
GCHPNGMRIFFYDSENPPGSEVLRI  307
ues 138 to 240) to a rat PON1 domain (100 amino acids, residues 208 to
re shaded. The PON1 domain shows 65% similarity with the SMP30
ccession No. XP_342640.
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counterparts.4. Discussion
In the present work, SMP30 from the rat liver was puriﬁed
to homogeneity and established as having potent DFPase ac-
tivity in the presence of MgCl2. Moreover, by analyzing this
eﬀect in SMP30 knockout mice, we proved that SMP30 is a
unique enzyme with the distinctive ability to hydrolyze DFP in
the liver.
Billecke et al. [15] reported that the mouse liver contains a
soluble enzyme that hydrolyzes organophosphates such as
DFP, sarine, tabun and soman and noted that enzyme’s sim-
ilarity to SMP30. However, because the enzyme activity in
their cell lysates expressing recombinant SMP30 was quite low,
they could not deﬁnitively identify it as DFPase. To determine
whether SMP30 actually has DFPase activity, we isolated
SMP30 from rat livers and puriﬁed the soluble fraction about
49-fold with about 2% recovery (Table 1). The elution proﬁle
on a Sephacryl S-200 HR showed a coincident single peak at a
position characteristic of SMP30 and DFP hydrolyzing activ-
ity (data not shown). These results conﬁrmed that SMP30 has
DFPase activity.
Little et al. [21] described an enzyme in the liver’s soluble
fraction and noted some DFPase activity in the absence of
metal ions. However, our puriﬁed SMP30 had no DFPase
activity unless a divalent cation was present. In fact, 1 mM
MgCl2, MnCl2 and CoCl2 all stimulated DFPase activity to
the same extent, and 1 mM CdCl2 did so to a lesser degree, but
1 mM CaCl2 had no such eﬀect. Possibly, even a slight amount
of endogenous divalent cation such as Mg2þ, Mn2þ, Co2þ and/
or Cd2þ in their soluble liver fraction was suﬃcient to stimu-
late DFPase activity.
Yamaguchi and Sugii [22] reported that SMP30 (regucalcin)
is a calcium-binding protein. Yet we could not detect any
DFPase activity at all in the presence of CaCl2. To resolve this
discrepancy, we examined the calcium-binding activity of
SMP30 on a nitrocellulose membrane using 45Ca2þ and au-
toradiography as described by Maruyama et al. [23]. Although
calmodulin clearly bound to 45Ca, puriﬁed SMP30, even a
large amount (40 lg), completely failed to bind (data not
shown). However, the possibility remained that calcium-
binding activity dissipated in the course of SDS–PAGE and
transfer to the nitrocellulose membrane. To eliminate that
possibility, we conducted equilibrium dialysis using 45Ca2þ and
a microdialyzer, essentially the same procedure described by
Yamaguchi and Sugii [22]. However, even then, the puriﬁed
SMP30 had no calcium-binding activity at all (data not
shown). Therefore, SMP30 does not seem to be a calcium-
binding protein.
The rat SMP30 domain has sequence similarity to a rat
serum PON1 domain (Fig. 3). PON family members, which
consist of PON1, PON2 and PON3, act as important
guardians against cellular damage from toxic agents, such as
organophosphates, oxidized lipids in the plasma low density
lipoprotein, and bacterial endotoxins [20]. In particular, like
SMP30, PON1 also hydrolyzes DFP in the presence of CaCl2
[24]. However, testing the substrate speciﬁcity of SMP30 re-
vealed a distinct diﬀerence between the two, because SMP30
did not hydrolyze any of several PON substrates, i.e.,paraoxon, dihydrocoumarin, c-nonalactone, and d-dodecan-
olactone (Table 3). Thus, SMP30 is distinct from the PON
family.
Our previously established SMP30 knockout mice [13]
enabled us to compare DFPase activity in their livers to that
in SMP30-replete wild-type mice. Accordingly, livers from
these wild-type mice had readily detectable DFPase activity,
whereas in liver from SMP30 knockout mice did not.
Moreover, in vitro, SMP30 knockout hepatocytes were
highly susceptible to DFP-induced cytotoxicity. These results
indicated that SMP30 is a unique DFP hydrolyzing enzyme
with the important eﬀect of neutralizing DFP toxicity in the
liver. In support, our previous ﬁndings revealed that the
livers of SMP30 knockout mouse were highly susceptible to
TNF-a and Fas-mediated apoptosis [13]. Collectively, these
outcomes denote that a reduction of SMP30 expression
might account for the age-associated deterioration of cellular
functions and enhanced susceptibility to harmful stimuli in
aged tissue.
Mammalian SMP30 shows high levels of homology with
deduced amino acid sequences for luciferin-regenerating en-
zyme (LRE) in ﬁreﬂies [25]. LRE is a single polypeptide
with a molecular mass of 38 kDa and is capable of con-
verting oxyluciferin to 2-cyano-6-hydroxybenzothiazole that,
in turn, is converted into luciferin in the presence of D-
cysteine. Because of their similarity, we examined whether
LRE has DFPase activity and whether SMP30 has LRE
activity. Testing with recombinant LRE located DFPase
activity with approximately half the speciﬁc activity of
SMP30 (data not shown). However, SMP30 had no detect-
able LRE activity. These results strongly suggested that
DFPase activity is a common function for SMP30 and that
LRE activity has evolved as a new function of converting
oxyluciferin into 2-cyano-6hydroxybenzothiazole speciﬁcally
in ﬁreﬂies.
From the results reported in this paper, we conclude that
SMP30 is a unique enzyme, whose ability to hydrolyze DFP
protects the liver from its toxic eﬀects. However, the physio-
logical substrate remains unclear, because DFP is an artiﬁcial
chemical compound. Recently, we found abnormal accumu-
lations of such phospholipids as phosphatidylethanolamine,
cardiolipin, phosphatidylcholine, phosphatidylserine and
sphingomyelin in the livers of SMP30 knockout mice [14].
Because the chemical structure of phospholipids includes or-
ganophosphate, we tested directly if SMP30 has phospholipid
catabolic activity like that of phospholipase C (PLC) and
phospholipase D (PLD). However, we did not detect notable
PLC or PLD activity even when a large amount of puriﬁed rat
SMP30 was used (data not shown). The future identiﬁcation of
SMP30’s physiological substrate bears a strong potential for
increasing our understanding of this interesting and important
molecule.
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